Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Sacituzumab Govitecan Approaches EU Approval for Pretreated HR+ Metastatic Breast Cancer

June 23rd 2023

The EMA's Committee for Medicinal Products for Human Use has adopted a positive opinion regarding sacituzumab govitecan-hziy monotherapy in select patients with unresectable or metastatic hormone receptor–positive, HER2-negative breast cancer.

Dr Hamilton on the Investigation of HER3-DXd in ER+ Breast Cancer and TNBC

June 23rd 2023

Erika P. Hamilton, MD, discusses the investigation of patritumab deruxtecan in heavily pretreated patients with metastatic estrogen receptor-positive or triple-negative breast cancer with varying levels of HER3 expression in a phase 2 trial.

Dr Pistilli on Understanding Dynamic HER2 Expression in Metastatic Breast Cancer

June 22nd 2023

Barbara Pistilli, MD, discusses the importance of understanding how HER2 expression can change over time when assessing target expression in metastatic breast cancer.

Addressing Chemotherapy-Induced Menopause in Patients With Breast Cancer

June 21st 2023

Focused discussion on the incidence of chemotherapy-induced menopause in patients receiving treatment for their breast cancer.

Prevalence of Premenopausal Patients With Breast Cancer

June 21st 2023

Expert oncologists Matteo Lambertini, MD, PhD, and Virginia Kaklamani, MD, DSc, reflect on the subset of patients with breast cancer who are premenopausal and how that impacts their approach to disease management.

Dr Rosen on the Activity of Zotatifin Plus Abemaciclib/Fulvestrant in ER+ Breast Cancer

June 19th 2023

Ezra Rosen, MD, PhD, discusses the investigation of the triplet combination of zotatifin, abemaciclib, and fulvestrant in a phase 1/2 trial in heavily pretreated patients with estrogen receptor-positive metastatic breast cancer.

Dr Vidula on the Evaluation of Talazoparib in BRCA1/2-Mutated Metastatic Breast Cancer

June 19th 2023

Neelima Vidula, MD, discusses an ongoing phase 2 study evaluating the highly potent PARP inhibitor talazoparib in patients with somatic BRCA1/2-mutated metastatic breast cancer.

HER2+ Metastatic Breast Cancer: Unmet Needs and Future Directions in Care

June 19th 2023

Closing out her discussion on HER2+ metastatic breast cancer, expert oncologist Virginia Kaklamani, MD, DSc, highlights ongoing unmet needs future directions in care.

Addressing Resistance to HER2-Targeted Therapy in Metastatic Breast Cancer

June 19th 2023

Comprehensive insight on acquired resistance to HER2-targeted therapy in metastatic breast cancer, and how treatments can be selected and sequenced thereafter.

Dr Elkhanany on Biological Drivers of Progression in ER+ Metastatic Breast Cancer

June 15th 2023

Ahmed Elkhanany, MD, discusses biological drivers of disease in patients with estrogen receptor–positive breast cancer who have disease progression shortly after initiating first-line therapy, as well as the importance of performing comprehensive genetic testing in these patients to determine subsequent treatment approaches.

Gedatolisib Triplet Shows Early Efficacy in Previously Untreated ER+/HER2– Breast Cancer

June 15th 2023

The addition of gedatolisib to palbociclib and letrozole produced durable responses with comparable safety to that observed with palbociclib and letrozole alone in treatment-naïve patients with estrogen receptor-positive, HER2-negative advanced breast cancer.

Dr Goel on the Preliminary Efficacy of Tinengotinib Monotherapy in Advanced Solid Tumors

June 13th 2023

Sanjay Goel, MD, MS, discusses the preliminary efficacy of tinengotinib monotherapy in advanced solid tumors according to data from a phase 1b/2 trial (NCT04742959).

FDA Grants Priority Review to Capivasertib Plus Fulvestrant in Advanced HR+ Breast Cancer

June 12th 2023

The FDA has accepted and granted priority review designation to the new drug application for the combination of capivasertib and fulvestrant for the treatment of patients with hormone receptor–positive, HER2-negative, locally advanced or metastatic breast cancer following recurrence or progression on or after endocrine-based therapy.

Role of Brain Metastases and Quality of Life in Treatment Decisionmaking

June 12th 2023

Virginia Kaklamani, MD, DSc, shares her perspective on the roles that brain metastases and quality of life play, respectively, in selecting treatment for HER2+ mBC.

Factors in Selecting Third-Line Therapy for HER2+ Metastatic Breast Cancer

June 12th 2023

Focused discussion on factors that help inform treatment selection for patients with HER2+ metastatic breast cancer in the third-line setting.

Dr Partridge on Breast Cancer Recurrence in Young Breast Cancer Survivors

June 9th 2023

Ann H. Partridge, MD, MPH, discusses the incidence of second primary breast cancer in young patients with a history of breast cancer.

Dr Waks on Survival Outcomes With Chemotherapy in Small Node-Negative HER2+ Breast Cancer

June 9th 2023

Adrienne G. Waks, MD, discusses breast cancer survival in patients with small node-negative HER2-positive breast cancer according to the treatment modality received.

Dr Hamilton on the Efficacy and Safety of Abemaciclib Plus ET in Elderly Patients With HR+/HER2- Breast Cancer

June 8th 2023

Erika P. Hamilton, MD, discusses the efficacy and safety of adjuvant abemaciclib plus endocrine therapy in patients with hormone receptor–positive, HER2-negative, high-risk early breast cancer according to age.

Dr Bardia on Results of the NATALEE Trial in HR+/HER2– Early Breast Cancer

June 7th 2023

Aditya Bardia, MD, MPH, discusses the investigation of ribociclib and endocrine therapy vs endocrine therapy alone as adjuvant treatment in patients with hormone receptor-positive/HER2-negative early breast cancer, highlighting primary results from the phase 3 NATALEE trial.

Dr Tolaney on Final OS Data From the TROPiCS-02 Trial in HR+/HER2- Breast Cancer

June 7th 2023

Sara M. Tolaney, MD, MPH, discusses key data from a final overall survival analysis of the phase 3 TROPiCS-02 trial in hormone receptor–positive, HER2-negative breast cancer.